

Curriculum Vitae

PERSONAL INFORMATION

- Name: Mona El-Bahrawy
- Date of Birth: 25 February 1967
- Address: Department of Histopathology
Hammersmith Hospital
DuCane Road
London W12 0NN
United Kingdom

- Phone: 00 44 (0)20 8383 3442 (Work)
00 44 (0)7771 574 968 (Mobile)

- E-mail: m.elbahrawy@imperial.ac.uk

EDUCATION AND QUALIFICATIONS

- **2016** *Cardiff University Law School Bond Solon Expert Witness Certificate (Civil)*

- **2008** *Fellowship of the Royal College of Pathologists*

- **2003** *Membership of the Royal College of Pathologists*

- **2002** *PhD* Imperial College, University of London, United Kingdom.

- **1995** *MSc Pathology* Faculty of Medicine, University of Alexandria, Egypt.

- **1989** *MBBCh* Faculty of Medicine, University of Alexandria, Egypt.

PROFESSIONAL EXPERIENCE

- **August 2012 – present:** Associate Professor, Alexandria Faculty of Medicine.
- **October 2005 – present** Adjunct Reader and Consultant Histopathologist at the Department of Histopathology, Imperial College London.
- **January – July 2011:** Reporting urologic pathology cases for Bostwick Laboratories, London.
- **June – August 2005** Locum consultant at the Department of Histopathology, Whipps Cross University Hospital.
- **February 2004 – May 2005** Locum consultant at the Department of Histopathology, Charing Cross Hospital.
- **2001 – 2004** Specialist registrar in the North Thames Region, London. The training was in the Departments of Histopathology at Hammersmith Hospital/Charing Cross Hospitals (24 months), Royal Marsden Hospital (6 months) and Chelmsford Essex Centre (3 months).
- **1997 – 2001** PhD student at Imperial College London.
- **1996- 1997** Assistant Lecturer in the Department of Pathology, Faculty of Medicine, University of Alexandria, Egypt.
- **1991- 1996** Registrar and demonstrator in the Department of Pathology, Faculty

of Medicine, University of Alexandria, Egypt.

- **1990- 1991** House officer Alexandria University Hospitals, Alexandria, Egypt

EXPERIENCE IN AUDIT

I attended the “Audit Workshop” organised by the Royal College of Pathologists in November 2000.

I carried out the following audit projects:

- Auditing Colorectal cancer pathology reporting
- Auditing cyto-histological correlation in patients with pleural effusions
- Auditing reporting of prostate core biopsies.
- Frozen section diagnosis in gynaecologic oncology
- Auditing the correlation between grading of dysplasia in cervical biopsies and subsequent cervical cones
- Auditing the correlation between grading of endometrial carcinoma in endometrial curettings and hysterectomy specimens.
- The impact of extensive cytoreductive surgery for ovarian cancer on the histopathology laboratory workload.
- Audit of turnaround time of reporting resections for tumour debulking surgery for patients with ovarian carcinoma undergoing extensive cytoreductive surgery.
- Participated in the Audit of invasive cervical cancers of the NHS cervical screening programme.

▪

PUBLICATIONS

1. Moulla A, Magdy N, **El-Bahrawy M**. Ovarian leiomyoma with myxoid stroma. *Pathologica* In press
2. Jones BP, Saso S, Farren J, **El-Bahrawy M**, Ghaem-Maghamsi S, Smith JR, Yazbek J. Ultrasound-Guided Laparoscopic Ovarian Wedge Resection in Recurrent Serous Borderline Ovarian Tumours. *Int J Gynecol Cancer* 2017 ;27(9):1813-18
3. El-Masry A, **El-Bahrawy M**. The impact of extensive cytoreductive surgery for ovarian cancer on the histopathology workload. *J Cytol Histol* 2017;8(2): DOI: 10.4172/2157-7099.1000454
4. Zanini E, Louis LS, Antony J, Karali E, Okon I, McKie AB, Vaughan S, **El-Bahrawy M**, Stebbing J, Recchi C and Gabra H. The tumour suppressor protein OPCML potentiates anti-EGFR and anti-HER2 targeted therapy in HER2-positive ovarian and breast cancer. *Molecular Cancer*

- Therapeutics* 2017;16(10):2246-56.
5. Jones B, Saso S, Farren J, **El-Bahrawy M**, Smith R, Yazebek J. Intraoperative ultrasound guided laparoscopic ovarian tissue preserving surgery in the treatment of recurrent borderline ovarian tumours. *Ultrasound Obstet Gynecol* 2017;50(3):405-6
 6. Westaby J, Magdy N, Fisher C, **El-Bahrawy M**. Primary Ovarian Malignant PEComa – A case report. *IJGP* 2017;36(4):400-4
 7. Hartwig T, Montinaro A, von Karstedt S, Sevko A, Surinova S, Chakravarthy A, Taraborrelli L, Draber P, Lafont E, Vargas FA, **El-Bahrawy MA**, Quezada SA, Walczak H. The TRAIL-Induced cancer secretome promotes a tumor-Supportive immune microenvironment via CCR2. *Mol Cell* 2017;16;65(4):730-42
 8. Rzepecka IK, Szafron L, Stys A, Felisiak-Golabek A, Podgorska A, Pienkowska-Grela B, Timorek A, Sobiczewski P, **El-Bahrawy M**, Kupryjanczyk J. Prognosis of patients with *BRCA1* – associated ovarian carcinomas depends on TP53 accumulation status in tumor cells. *Gynecol Oncol* 2017;144(2):369-76
 9. Wang J, Truvedi P, **El-Bahrawy M**. Positivity rate of TTF-1 on immunohistochemistry in pancreatic neuroendocrine tumours. *Pathol Int* 2016;66(12):708-9
 10. Konopk B, Szafron LM, Kwiathowska E, Podgorska A, Zolocinska A, Pienkowska-Grela B, Balcerak A, Lukasik M, Stachurska A, Timorek A, Spiewankiewicz B, **El-Bahrawy M** and Kupryjanczyk J. The significance of c.690g>t polymorphism (rs34529039) and expression of the *CEBPA* gene in ovarian cancer risk and outcome. *Oncotarget* 2016;7(41):67412-24
 11. Alzoubi S, Brody L, Rahman S, Mellier A, Mercado N, Ito K, Poulosom R, **El-Bahrawy M**, Silver A, Boobis A, Bell J, Hajji N. Synergy between histone deacetylase inhibitors and DNA-damaging agents is mediated by histone deacetylase 2 in colorectal cancer. *Oncotarget* 2016 Jul 12;7(28):44505-21
 12. Stavrinou S, Irving JA, Lee CH, Oliva E, Young RH, Sriraksa R, Clarke A, Magdy N, Van Noorden S, McCluggage WG, **El-Bahrawy M**. Differential expression of E-cadherin and catenins in ovarian sex cord stromal tumors. *Histopathol* 2016;69(2):298-306
 13. Moulla A, Magdy N, Francis N, Taube J, Ronnett B, **El-Bahrawy M**. Rare skin adnexal and melanocytic tumors arising in ovarian mature cystic teratomas: a report of 3 cases and review of the literature. *IJGP* 2016;35(5):448-55
 14. Showeil R, Romani C, Valganon M, Lambrous M, Truvedi P, van Noorden S, Sriraksa R, El-Kaffash, El-Etreby N, Natrajan R, Fironi L, Osborne R, **El-Bahrawy M**. The Status of Epidermal Growth Factor Receptor in Borderline Ovarian Tumours. *Oncotarget* 2017;7(9):10568-77
 15. Kyriakides M, Rama N, Sidhu J, Gabra H, Keun H, **El-Bahrawy M**. Metabonomic analysis of ovarian tumour cyst fluid by proton nuclear magnetic resonance spectroscopy. *Oncotarget* 2016;7(6):7216-26
 16. Hopkins TG, Mura M, Al-Ashtal HA, Lahr RM, Abd-Latip N, Sweeney K, Lu H, Weir J, **El-Bahrawy M**, Steel JH, Ghaem-Maghani S, Aboagye EO, Berman AJ, Blagden SP. The RNA-binding protein LARP1 regulates survival and tumorigenesis in ovarian cancer. *Nuc Acid Res* 2016;44(3):1227-46.

17. Flower K, Shenker S, **El-Bahrawy M**, Goldgar D, Parsons M, KConFab Investigators, AFFECT study group, Spurdle M, Morris J, Brown R, Flanagan J. DNA methylation profiling to assess pathogenicity of *BRCA1* unclassified variants in breast cancer. *Epigenetics* 2015;10(12):1121-32.
18. Gungor H, Saleem A, Babar S, Dina R, **El-Bahrawy M**, Rama N, Chen M, Pickford E, Agarwal R, Blagden S, Carme S, Salinas C, Madison SJ, Krachey EC, Santiago-Walker A, Smith DA, Morris SR, Stronach EA, Gabra H. Dose-finding quantitative FDG PET imaging study with the oral pan-AKT inhibitor GSK2141795 in patients with gynaecological malignancies. *J Nuc Med* 2015;56(12):1828-35
19. Stronach EA, Cunnea P, Turner C, Guney T, Aiyappa R, Jeyapalan S, de Sousa C, Browne A, Magdy N, Studd J, Sriraksa R, Gabra H, **El-Bahrawy M**. The role of Interleukin-8 (IL-8) and IL-8 receptors in platinum response in high grade serous ovarian carcinoma. *Oncotarget*. 2015;6(31):31593-603.
20. Shenker NS, Flower KJ, Wilhelm-Benartzi C, Dai W, Bell E, Gore E, **El-Bahrawy M**, Weaver G, Brown R and Flanagan JM. Transcriptional implications of intragenic DNA methylation in the oestrogen receptor alpha gene in breast cancer cells and tissues. *BMC Cancer* 2015;15:337
21. von Karstedt S, Conti A, Nobis M, Montinaro A, Hartwig T, Lemke J, Legler K, Annewanter F, Campbell AD, Taraborrelli L, Grosse-Wilde A, Coy J, **El-Bahrawy MA**, Bergmann F, Koschny R, Werner J, Ganten TM, Schweiger T, Hoetzenecker K, Kenessey I, Hegedüs B, Bergmann M, Hauser C, Egberts J, Becker T, Röcken C, Kalthoff H, Trauzold A, Anderson KI, Sansom OJ, Walczak H. Cancer-cell-autonomous TRAIL-R signaling promotes KRAS-driven cancer progression, invasion and metastasis. *Cancer Cell* 2015; 27:561-73.
22. Kovac M, Navas C, Horswell S, Salm M, Bardella C, Rowan A, Castro-Giner F, Jones A, Howarth K, Fisher R, Kovacova M, Williams J, Gorman M, Jaeger E, Larkin J, Stares M, Pickering L, Gore M, Nicol D, Hazell S, Stamp G, O'Brien T, Challacombe B, Matthews N, Phillimore B, Begum S, Rabinowitz A, Varela I, Chandra A, Horsfield C, Polson A, Terracciano L, Eppenberger-Castori S, Protheroe A, Maher E, **El Bahrawy M**, Fleming S, Ratcliffe P, Heinimann K, Swanton C, Tomlinson I. Recurrent chromosomal gains and heterogeneous driver mutations characterise papillary renal cancer evolution. *Nat Comm* 2015;6:6336
23. Wang J, Papanastasopoulos P, Savage P, Smith J, Fisher C, **El-Bahrawy M**. A unique case of extra-ovarian sex-cord stromal fibrosarcoma, with subsequent relapse of differentiated sex-cord tumor. *Int J Gynaecol Pathol* 2015;34(4):363-8
24. Wang J, **El-Bahrawy M**. Expression profile of mucins (MUC1, MUC2, MUC5AC and MUC6) in ovarian mucinous tumours: changes in expressions from benign to malignant tumours. *Histopathology* 2015; 66:529-35
25. Alsolami S, **El-Bahrawy M**, Kalloger S, AlDaoud N, Pathak TB, Cheung C, Mulligan AM, Tomlinson IP, Pollard PJ, Gilks CB, W McCluggage G, Clarke BA. Current Morphologic Criteria Perform Poorly in Identifying Hereditary Leiomyomatosis and Renal Cell Carcinoma Syndrome Associated Uterine Leiomyomas. *Int J Gynecol Pathol* 2014;33:560-7
26. Hedley C, Van Noorden S, Sriraksa R, **El-Bahrawy M**. The frequency

- and significance of WT-1 expression in serous endometrial carcinoma. *Hum Pathol.* 2014;45:1879-84
27. Wang J, Taylor A, Showeil R, Trivedi P, Horimoto Y, Bagwan I, Ewington L, Lam E, **El-Bahrawy M**. Expression profiling and prognostic significance of VEGF-A, VEGFR2, VEGFR3 and related proteins involved in tumour angiogenesis in endometrial carcinoma. *Cytokine* 2014;68:94-100
 28. **El-Bahrawy M**, Ganesan R. Frozen section in gynaecology: uses and limitations. *Arch Gynecol Obstet.* 2014;289:1165-70
 29. **El-Bahrawy M**. Fertility and Gynaecological Oncology. *WJOG* 2014;3:26-7
 30. Magdy N, **El-Bahrawy M**. The fallopian tube: its role in infertility and gynaecological oncology. *WJOG* 2014;3:35-41
 31. Khoo I, Van Noorden S, **El-Bahrawy M**. The numbers and distribution of Interstitial cells of Cajal in Fallopian tubes with ectopic gestation. *Advances in Research* 2014;2:376-86
 32. Martins M, McCarthy A, Baxindale R, Guichard S, **El-Bahrawy M**, Lorenza M, Katan M. Tumour suppressor role of phospholipase C epsilon in Ras-triggered cancers. *PNAS* 2014;111:4239-44
 33. Curry E, Stronach E, Rama N, Wang Y, Gabra H, **El-Bahrawy M**. Molecular subtypes of serous borderline ovarian tumors show distinct expression patterns of benign tumor and malignant tumor associated signatures. *Modern Pathol.* 2014;27:433-42
 34. Wang J, **El-Bahrawy M**. Expression profile of mucins (MUC1, MUC2, MUC5AC and MUC6) in ovarian mucinous tumors: distinguishing primary ovarian from metastatic tumors. *Int J Gynaecol Pathol.* 2014;33:166-75
 35. Lemke J, von Karstedt S, Abd El Hay M, Papenfuss K, Montinaro A, Conti A, Arce F, **El-Bahrawy M**, Walczak H. Selective CDK9 inhibition overcomes TRAIL resistance by concomitant suppression of cFlip and Mcl-1. *Cell Death and Differentiation.* 2014;2:491-502
 36. Zhao L, Ashek A, Wang L, Fang W, Pullamsetti S, Dubois O, Cupitt J, Dabra S, Cotroneo E, Jones H, Tomasi H, Nguyen Q, Aboagye E, **El-Bahrawy M**, Barnes G, Howard L, Gibbs S, Gsell W, He J, Wilkins M. Heterogeneity in lung 18FDG uptake in PAH: potential of dynamic ¹⁸FDG-PET with kinetic analysis as a bridging biomarker for pulmonary remodeling targeted treatments. *Circulation.* 2013;128:1214-1224
 37. Browne A, Srisranka R, Guney T, Rama N, Van Noorden S, Curry E, Gabra H, Stronach E, **El-Bahrawy M**. Differential expression of IL-8 and IL-8 receptors in benign, borderline and malignant ovarian epithelial tumours. *Cytokine.* 2013;64:413-21
 38. Iyer R, Chow J, **El-Bahrawy M**, Savage P. Meig's syndrome presenting with axillary vein thrombosis and lymphadenopathy: a case report. *J Med Case Reports.* 2013;15;7:182
 39. Beggs A, Jones A, **El-Bahrawy M**, Abulafi M, Hodgson S, Tomlinson I. Whole-genome methylation analysis of benign and malignant colorectal tumours. *J Pathol.* 2013;229:697-704
 40. Adam J, Yang M, Bauerschmidt C, Kitagawa M, O'Flaherty L, Rossell S, Maheswaran P, Zheng L, Notebaart RA, Özkan G, Sahgal N, Baban D, Kato K, Saito K, Stratford M, Guade E, Pugh C, Tenant D, Ludwig C,

- Frezza C, Davies B, Ratcliffe P, **El-Bahrawy M**, Ashrafiyan H, Soga T, Pollard PJ. A Role For Cytosolic Fumarate Hydratase In Urea Cycle Metabolism And Renal Neoplasia. *Cell Reports* 2013;30:1440-8
41. Wang J, El-Masry M, Talbot I, Tomlinson I, Alison M, **El-Bahrawy M**. Expression profiling of proliferation and apoptotic markers along the adenoma-carcinoma sequence in Familial Adenomatous Polyposis patients. *Gastroenterology Research and Practice*. 2013;2013:1-7
 42. Zeller C, Dai W, Curry E W, Siddiq A, Walley A, Masrouf N, Kitsou-Mylona I, Anderson G, Ghaem-Maghami S, Brown R, **El-Bahrawy M**. The DNA methylomes of serous borderline tumours reveal subgroups with malignant-like or benign-like profiles. *Am J Pathol*. 2013 ;182:668-77
 43. Pellegrino L, Stebbing J, Braga VM, Frampton AE, Jacob J, Buluwela L, Jiao LR, Periyasamy M, Madsen CD, Caley MP, Ottaviani S, Roca-Alonso L, **El-Bahrawy M**, Coombes RC, Krell J, Castellano L R-23b regulates cytoskeletal remodeling, motility and metastasis by directly targeting multiple transcripts. *Nuc Acid Res*. 2013; 41: 5400-12
 44. Stempe-Hale K, Shipman K, Kitsou-Mylona I, Gonzalez de Castro D, Hird V, Brown R, Flanagan J, Gabra H, Mills G, Agarwal R, **El-Bahrawy M**. Frequency of mutations and polymorphisms in borderline ovarian tumours of known cancer genes. *Modern Pathol*. 2013;26:544-52
 45. Ganesan R, Brown L, Kehoe S, McLugagge GW, **El-Bahrawy M**. The role of frozen sections in gynaecological oncology: survey of the practice in the United Kingdom. *EJOGRB*. 2013;166:204-8
 46. Coombes R, Tat T, Miller M, Reise J, Mansi J, Hadjiminis D, Shousha S, Elsheikh S, Lam E, Horimoto Y, **El-Bahrawy M**, Aboagye E, Contractor K, Shaw J, Walker R, Palmieri C, Stebbing J. An Open-Label Study of Lapatinib in Women with HER-2 Negative Early Breast Cancer: the Lapatinib Pre-Surgical Study (LPS Study). *Annals Oncol* 2013;24:924-30
 47. Winser A, Ledermann J, Osborne R, Gabra H, **El-Bahrawy M**. A Survey of the Management of Borderline Ovarian Tumours in the United Kingdom. *WJOG* 2012;1:3-13
 48. Balasubramaniam ES, Van Noorden S, **El-Bahrawy M**. The Expression of IL-6, IL-8 and their Receptors in Fallopian Tubes with Ectopic Tubal Gestation. *Fertil Steril* 2012;98:898-904
 49. Ewington L, Taylor A, Sriraksa R, Horimoto Y, Lam E, **El-Bahrawy M**. The expression of interleukin-8 and interleukin-8 receptors in endometrial carcinoma. *Cytokine* 2012;59:417-22
 50. Guppy NJ, **El-Bahrawy ME**, Kocher H, Fritsch K, Kureshi YA, Poulosom R, Jeffery R, Wright NA, Alison MR and Otto WR. Trefoil Factor Family Peptides in Normal and Diseased Human Pancreas. *Pancreas* 2012;41:888-96
 51. Wang J, Hollingshead J, El-Masry N, Horncastle D, Talbot I, Tomlinson I, Alison MR, **El-Bahrawy M**. Expression of EGFR, HER2, phosphorylated ERK and phosphorylated MEK in colonic neoplasms of familial adenomatous polyposis patients. *J Gastrointest Cancer* 2012;43:444-55
 52. Wang J, **El-Bahrawy M**. The diagnostic accuracy of cervical biopsies in determining cervical lesions. *Pathologica* 2011;103:331-6
 53. McKie A, Vaughan S, Okon I, Zanini E, Shapshnikov D, Wong J, Gungor H, Janczar S, Agarwal R, **El-Bahrawy M**, Lam E, Chayen N, Gabra H. The OPCML Tumor Suppressor Functions as a Cell Surface Repressor-

Adaptor, Negatively Regulating Receptor Tyrosine Kinases in Epithelial Ovarian Cancer with Therapeutic Implications. *Cancer Discovery* 2012;2:156-71

54. Adam J, Hatipoglu E, O'Flaherty L, Ternette N, Segal N, Lockstone H, Baban D, Nye E, Stamp G, Carmeliet P, Maxwell P, Frizzell N, BKessler, Pugh C, **El-Bahrawy M**, Ratcliffe P, Pollard P. Fumarate mediated succination of KEAP1 activates NRF2 signalling in FH-deficient cells and is independent of the hypoxia pathway. *Cancer Cell* 2011;20:524-37
55. Flora R, Dubash S, Taylor A, **El-Bahrawy M**. Alpha-foetoprotein producing endometrial serous carcinoma. *JST* 2011;1 :83-86
56. Mashali N, Awad AT, Trevisen G, **El-Bahrawy M**. Renal leiomyoma. *Pathologica* 2011;103:22-4
57. Horimoto Y, Hartman J, Millour J, Pollock S, Olmos Y, Ho K, R. Coombes RC, Poutanen M, Mäkelä SI, **El-Bahrawy M**, Speirs V, Lam EWF. ER β 1 represses FOXM1 expression through ER α to control cell proliferation in breast cancer. *Am J Pathol* 2011;179:1148-56.
58. **El-Bahrawy M**. Alpha-foetoprotein producing non-germ cell tumours of the urological system. *Rev Urol* 2011;13:14-9
59. Bardella C, **El-Bahrawy M**, Frizzell N, Hatipoglu E, Howarth K, Adam J, O'Flaherty L, Roberts I, Turner G, Taylor J, Giaslakitotis K, Macaulay V, Harris AL, Chandra A, Lehtonen H, Launonen V, Aaltonen L, Pugh C, Mihai R, Baynes J, Ratcliffe PJ, Tomlinson I, Pollard PJ. Aberrant succination of proteins in fumarate hydratase-deficient mice and HLRCC patients is a robust biomarker of mutation status *J Pathol* 2011;225:4-11
60. **El-Bahrawy M**. Expression of p16 in post-radiotherapy cervical biopsies. *Histopathology* 2011 58:1174-6
61. Sriraksa R, Zeller C, **El-Bahrawy M**, Dai W, Daduang J, Jearanaikoon P, Chau-in S, Brown R, Limpai boon T. CpG-island methylation study of liver fluke-related cholangiocarcinoma. *Br J Cancer* 2011 104:1313-8
62. Tan DSP, Irvani M, McCluggage WG, Lambros MBK, Mackay A, Gourley C, Geyer FC, Vatcheva R, Millar J, Thomas K, Natrajan R, Savage K, Fenwick K, Williams A, Jameson C, **El-Bahrawy M**, Gore ME, Gabra H, Kaye SB, Ashworth A, Reis-Filho JS. Genomic analysis reveals the molecular heterogeneity of ovarian clear cell carcinomas. *Clin. Cancer Res* 2011 17:1521-34
63. Ashrafian H, O'Flaherty L, Adam J, Steeples V, Chung Y, East P, Vanharanta S, Lehtonen H, Nye E, Hatipoglu E, Miranda M, Howarth K, Shukla D, Troy H, Griffiths J, Spencer-Dene B, Yusuf M, Volpi E, Maxwell P, Stamp G, Poulson R, Pugh C, Costa B, Bardella C, Flavia Di Renzo M, Kotlikoff M, Launonen V, Aaltonen L, **El-Bahrawy M**, Tomlinson I, and Pollard P. Expression profiling in progressive stages of fumarate hydratase deficiency: The contribution of metabolic changes to tumorigenesis. *Cancer Research* 2010 15: 9153-65
64. Smith R, Moss J, Shore I, **El-Bahrawy M**. Juvenile granulosa cell tumour with hepatocyte-like cells and raised serum alpha-foetoprotein. *Histopathology* 2010 56:637-41
65. **El-Bahrawy M**. Alpha-foetoprotein producing non-germ cell tumours of the female genital tract. *Eur J Cancer* 2010 46:1317-22
66. **El-Bahrawy M**, Khorsandy S, Williamson R, Stamp W. Solid cystic pseudopapillary tumour of the pancreas, a new variant. *Pancreas* 2010

67. Syed F, Wang J, Ahmed R, Guest S, Lam E, Stamp G, **El-Bahrawy M**. IL-8 and IL-8 receptor expression in pancreatic adenocarcinoma and neuroendocrine tumours. *Cytokine* 2010 49:134-40.
68. Barker D, Sharma R, McIndoe A, Blair E, Hall M, Gabra H, **El-Bahrawy M**. An Unusual case of sex cord tumour with annular tubules with malignant transformation in a patient with Peutz-Jeghers Syndrome. *Int J Gynecol Pathol* 2010 29:27-32.
69. Fellous TG, McDonald SA, Burkert J, Humphries A, Islam S, De-Alwis NM, Gutierrez-Gonzalez L, Tadrous PJ, Elia G, Kocher HM, Bhattacharya S, Mears L, **El-Bahrawy M**, Turnbull DM, Taylor RW, Greaves LC, Chinnery PF, Day CP, Wright NA, Alison MR. A Methodological Approach to Tracing Cell Lineage in Human Epithelial Tissues. *Stem Cells* 2009 27:1410-20.
70. Tan DS, Lambros M, Rayter S, Natrajan R, Vatcheva R, Gao Q, Marchiò C, Geyer F, Savage K, Parry S, Fenwick K, Tamber N, Mackay A, Dexter T, Jameson C, McCluggage WG, Williams A, Graham A, Faratian D, **El-Bahrawy M**, Paige AJ, Gabra H, Gore ME, Zvelebil M, Lord CJ, Kaye SB, Ashworth A, Reis-Filho JS. PPM1D is a potential therapeutic target in ovarian clear cell carcinomas. *Clin Cancer Res* 2009 15:2269-80.
71. Bagwan IN, Moss J, Fisher C, **El-Bahrawy M**. Amianthoid-like fibres in leiomyoma. *Histopathology* 2008 53:606-9.
72. **El-Bahrawy M**, Khoubehi B, Hrouda D. Perirenal schwannoma: A case report. *J med case reports* 2008 2:189
73. **El-Bahrawy M**, Rowan A, Horncastle D, Tomlinson I, Theis B, Russell R, Stamp G. E-Cadherin/Catenin Complex Status in Solid Pseudopapillary Tumor of The Pancreas. *Am J Surg Path* 2008 32:1-7.
74. Pollard PJ, Spencer-Dene B, Shukla D, Howarth K, Nye E, **El-Bahrawy M**, Deheragoda M, Joannou M, McDonald S, Martin A, Igarashi P, Varsani-Brown S, Rosewekk I, Poulson R, Maxwell P, Stamp GW, Tomlinson IP. Targeted inactivation of fh1 causes proliferative renal cyst development and activation of the hypoxia pathway. *Cancer Cell* 2007 11:311-9.
75. Vanharanta S, Wortham NC, Langford C, **El-Bahrawy M**, van der Spuy Z, Sjoberg J, Lehtonen R, Karhy A, Tomlinson IP, Aaltonen LA. Definition of a minimal region of deletion of chromosome 7 in uterine leiomyomas by tiling-path microarray CGH and mutation analysis of known genes in this region. *Genes Chromosomes Cancer* 2007 46:451-8.
76. Pollard PJ, **El-Bahrawy M**, Poulson R, Elia G, Killick P, Kelly G, Hunt T, Jeffery R, Seedhar P, Barwell, Latif F, Gleeson MJ, Hodgson SV, Stamp GW, Tomlinson IP, Maher ER. Expression of HIF-1{alpha}, HIF-2{alpha} (EPAS1), and their target genes in paraganglioma and pheochromocytoma with VHL and SDH mutations. *J Clin Endocrinol Metab* 2006 91:4593-8
77. Carjaval-Carmona LG, Alam NA, Pollard PJ, Jones AM, Barclay E, Wortham M, Pignatelli M, Freeman A, Pomplun S, Ellis I, Poulson R, **El-Bahrawy MA**, Berney DM, Tomlinson I. Ault Leydig-cell tumours of the testis caused by germline fumarate hydratase mutations. *J Clin Endocrinol Metab* 2006; 91:3071-5
78. Shams PN, Hardy T, **El-Bahrawy M**, Joshi N. Syringocystadenoma

- papilliferum of the eyelid in a young girl: a management dilemma and review of the literature. *Ophthal Plast Reconstr Surg* 2006; 22:67-69.
79. Hagmann C, **El-Bahrawy M**, Stamp G, Abel RM. Juvenile xanthogranuloma: a case report of a preterm baby. *J Pediatr Surg* 2006; 41:573-5
80. Behranwala KA, Chettiar K, **El-Bahrawy M**, Stamp GWH, Kakkar AK. Retroperitoneal myolipoma- a benign entity. *World J Surg Oncol* 2005; 3: 72
81. Madhurvrata P, Jayachandran MC, Edmonds DK, Agrawal S, **El-Bahrawy M**. Retroperitoneal solitary fibrous tumour arising from the pelvis in women--a case report and review of literature. *J Obstet Gynaecol* 2005; 25: 189-92.
82. **El-Bahrawy M**, Poulson R, Rowan A, Tomlinson I, Alison MR. Characterization of the E-cadherin/catenin complex in colorectal carcinoma cell lines. *Int J Exp Pathol* 2004; 85: 65-74.
83. **El Bahrawy M**, El Masry N, Alison M, Poulson R, Fallowfield M. Expression of β -catenin in basal cell carcinoma. *Br J Dermatol* 2003; 148: 964-70.
84. **El Bahrawy M**, Talbot I, Poulson R, Alison M. Variable nuclear localisation of α -catenin in colorectal carcinoma. *Lab Invest* 2002; 82: 1167-74.
85. **El Bahrawy M**, Talbot I, Poulson R, Jeffery R, Alison M. The expression of E-cadherin and catenins in colorectal tumours from familial adenomatous polyposis patients. *J Pathol* 2002; 198: 69-76.
86. **El Bahrawy M**, Poulson R, Jeffery R, Talbot I, Alison M. The expression of E-cadherin and catenins in sporadic colorectal carcinoma. *Human Pathol* 2001;32:1216-24.
87. **El Bahrawy MA**, Pignatelli M. E-cadherin and catenins: molecules with versatile roles in normal and neoplastic epithelial cell biology. *Microsc Res Tech* 1998;43:224-32.

MEETINGS ORGANISATION, INVITED LECTURES AND CONFERENCE PRESENTATIONS

Organisation of the FRCPath Part II exam preparation course, Cairo, Egypt, January 2018.

Organisation of the molecular pathology session of Immigrant Egyptian Oncology Summit 2016 and 2017 Luxor, Egypt.

Participation in the organisation of the Histopathology Trainee Development Day by the RCPATH and the ECPT, Egypt, July 2017.

Participation in the organisation of the first International Pathology Summer School by the RCPATH in partnership with the Armed Forces College of Medicine and the ECPT, Egypt, July 2017.

Organisation of the Joint ECPT/IMC Conference for Laboratory Medicine in collaboration with the Royal College of Pathologists, September 2016.

Organisation The Annual Meeting of the British Association of Gynaecological Pathology, 2014, 2015 and 2016.

Participation in the organisation of the Trainee Development Day and the Middle East and North Africa Conference: Postgraduate Specialty Training, Assessment and Examinations in Pathology & Laboratory Medicine. Joint meetings between the Royal College of Pathologists and the Egyptian Committee for Pathology Training, Cairo, April 2015

Organisation of Cervical pathology course for the British Association of Gynaecological Pathologists, 2014 and 2015

Organisation of ovarian pathology course for the British Association of Gynaecological Pathologists, November 2013

Organisation of endometrial pathology course for the British Association of Gynaecological Pathologists, September 2013, 2015

Organisation of one day course at the Royal College of Pathologists, London UK, entitled "Gynaecological Pathology Study day", March 2013

Organisation of one day course at the Royal College of Pathologists, London UK entitled "Is it primary or metastatic ? ", February 2011

Invited Lectures:

Masterclass in Gynaecological Oncology, Imperial College London, November 2017: The interesting aspects in the histopathological diagnosis of cervical cancer.

Annual Conference of the Egyptian Society of Pathology / Egyptian Committee for Pathology Training Joint Conference, Egypt, October 2017:

- Endometrial stromal lesions
- Serous tumours of the ovary
- Lower female genital tract slide seminar

RCPATH International Pathology Summer School, Egypt, July 2017: How to make a diagnosis.

Annual meeting of the British Association of Gynaecological Pathologists, London, May 2017: What is new in gynaecological pathology since May 2016

SurgiAlex 2017, Alexandria, Egypt, April 2017: The Multidisciplinary; The case in management of breast cancer

Immigrant Egyptian Oncology Forum, Luxor, Egypt, December 2016: Molecular Oncology: Towards a strategy of developing optimal service.

International Pathology Day, RCPATH, London, November 2016: Panel member in the round table panel discussion "How can we strengthen pathology education & training in low and middle-income countries?",

SUN 6th Annual Conference, Cairo, Egypt, October 2016:

- The multidisciplinary team
- The role of the pathologist in hereditary cancer syndromes

Update on Gynaecological Pathology Workshop, Alexandria University, Egypt, 17 December 2015

- Undifferentiated and miscellaneous tumours of the ovary
- Minimum datasets for reporting of endometrial carcinoma
- Case presentations

SUN 5th Annual Conference: Updates in Breast and Gastrointestinal malignancies, Alexandria, December 2015.

- Reflections on mucinous carcinoma: The breast and the large bowel
- Challenges from the Appendix

London Cancer Alliance Forum, London, November 2015: Pathology of borderline ovarian tumours

Trainee Development Day, Joint meeting between the Royal College of Pathologists and the Egyptian Committee for Pathology Training, Cairo, April 2015:

- Tissue Pathways
- Minimum datasets for cancer reporting

Middle East and North Africa Conference: Postgraduate Specialty Training, Assessment and Examinations in Pathology & Laboratory Medicine. Joint meeting between the Royal College of Pathologists and the Egyptian Committee for Pathology Training, Cairo, April 2015

- Implementing a new Egyptian model for training, supervision and assessment.

7th Meeting of the Royal Medical Services and 4th ICMM Pan Arab Regional Working Group Congress on Military Medicine. Jordan, November 2014

- Pathological diagnosis of endometrial carcinoma
- Recent advances in ovarian epithelial tumours
- Update on borderline ovarian tumours
- Meet the expert: slide seminar on gynaecological pathology

Pathologists and Oncologists, organised by SUN, Alexandria, Egypt, 2014.

- Immunohistochemistry in tumour diagnosis; value and limitations
- Immunohistochemistry beyond tumour diagnosis

British Association of Gynaecological Pathologists Ovarian Pathology course, Birmingham, November 2013:

- Differential diagnosis of primitive germ cell tumours
- Pathology of undifferentiated and miscellaneous ovarian neoplasms

British Association of Gynaecological Pathologists Endometrial pathology course, London, September 2013:

- Polypoid lesions of the endometrium

Molecular pathology study day – London Deanery, November 2013: Molecular pathology of ovarian cancer.

Urological malignancies conference, Alexandria, Egypt, April 2013:

- Pathology of renal malignancies
- Pathology of prostate cancer
- Four case presentations

Work shop on Gynaecological Pathology, Alexandria, Egypt, January 2013:

- Borderline ovarian tumours
- Developments in cancer genetics
- Two slide seminars: Cervical lesions
Uterine lesions

The Royal College of Obstetricians and Gynaecologist, October 2012:
Developments in cancer genetics for gynaecologists.

University College London, February 2009: Borderline ovarian tumours.

MEMBERSHIP OF PROFESSIONAL BODIES

- Principal Founder and Vice President of the Egyptian Committee for Pathology Training, August 2016
- Country Advisor for Egypt for the Royal College of Pathologists, February 2016
- Members of Learning and Professional Development Working Group, RCPATH
- Appointment to the Panel of Examiners in Histopathology, September 2015
- Member, UK Pathology Diaspora Forum, The Royal College of Pathologists.
- Member of the International Society of Gynaecological Pathologists
- Member of the British Association of Gynaecological Pathologists
- Council member of the British Association of Gynaecological Pathologists (November 2011-2016)
- Member of the Pathological Society of Great Britain and Ireland
- Member of the British Gynaecologic Cancer Society
- Member of the British Gynaecological Cancer Society Non-Surgical Oncology Subgroup
- Member of European Network for Translational Research in Ovarian Cancer
- Member of the Editorial Board of World Journal of Obstetrics and Gynecology
- Member of the Editorial Board of BioMed Research International
- Member of the Steering Committee of the National Gynaecological Pathology EQA scheme (2011-2014)

EXPERT WITNESS WORK

- I received The Cardiff University Law School Bond Solon Expert Witness Civil Certificate (2016)
- I have undergone the following expert witness training:
 - Excellence in report writing (2013)
 - Courtroom skills (2014)
 - Cross examination day (2014)
 - Civil Law and Procedure (2016)
- Listed on the United Kingdom General Medical Council expert list for the specialty of Histopathology
- I act as an Expert Witness in Medicolegal cases for the General Medical Council and Solicitor companies.

VOULANTARY OUTREACH ACTIVITIES

Founding member and representative fellow of the RCPATH in the Egyptian Committee for Pathology Training.

Consultant for setting up Laboratory Services in Shefa Al-Orman Charity Cancer Hospital, Luxor, Egypt.

Consultant for the Egyptian Armed Forces College of Medicine in collaborations with UK Academic and Professional Institutions in the field of Medical Education and Training.

Volunteer in the Wellcome Museum of the Royal College of Surgeons – organisation and annotation of the gynaecological pathology specimens.

**PARTICIPATION IN REGISTERED UNITED KINGDOM
EXTERNAL QUALITY ASSURANCE (EQA) SCHEMES**

North Thames General Histopathology EQA scheme

National Gynaecological Pathology EQA scheme

National Urological Pathology EQA scheme